Fennec Pharmaceuticals (FENC) Corporate presentation summary

Transforming cancer care with PEDMARK®

• PEDMARK® is the first and only FDA-approved therapy for cisplatin-induced ototoxicity (CIO), endorsed in NCCN guidelines for AYA cancer patients.

• Protected by a robust IP portfolio, with U.S. market exclusivity until September 2033 and 10-year pediatric use marketing authorization.

• Achieved five consecutive quarters of revenue growth and $44 million in net revenue for 2025.

• Strong partnerships for global expansion, including Norgine in Europe and InPharmus in the GCC.

The burden of cisplatin-induced hearing loss

• Cisplatin is essential in treating various cancers but causes irreversible hearing loss in 60–90% of patients.

• Hearing loss can begin early in treatment and may progress after therapy ends, affecting both children and adults.

• Quality of life is significantly reduced, impacting speech, academic performance, social development, and emotional well-being.

• Lifetime costs for early-onset severe hearing loss can exceed $1 million, with major impacts on productivity and education.

PEDMARK®: Clinical value and guidelines

• PEDMARK® reduces the risk of hearing loss by ~50% without compromising cancer treatment efficacy.

• Recommended by NCCN Guidelines as a Category 2A preventative treatment for AYA patients with localized, non-metastatic tumors.

• No branded competitors in development and unique formulation with manageable side effects.